Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2020CancerOpen Access

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPashna N. MunshiDVDavid H. VesoleAJArtur Jurczyszyn

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Munshi et al. (2020) studied this question.

synapsesocial.com/papers/6a02a4d8a7089d64356511cbhttps://doi.org/10.1002/cncr.33171
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity2016 · 63 citations
  2. 2With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study2019 · 107 citations
  3. 3Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report2017 · 88 citations
  4. 4Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma2017 · 1,268 citations
  5. 5Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial2019 · 264 citations